Connect Biopharma Holdings (CNTB) Total Liabilities (2020 - 2026)

Connect Biopharma Holdings has disclosed Total Liabilities across 7 years of filings, most recently posting $16.6 million for Q2 2026.

• In Q2 2026, Total Liabilities rose 45.93% year-over-year to $16.6 million; the TTM figure through Jun 2026 stood at $16.6 million (up 45.93% YoY), while the FY2025 annual figure was $14.1 million, up 54.58% from the prior year.
• Total Liabilities came in at $16.6 million for Q2 2026 at Connect Biopharma Holdings, down from $17.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $25.9 million in Q4 2023 to a low of -$100.6 million in Q3 2024.
• Average Total Liabilities over 5 years is -$1.1 million, with a median of $13.0 million recorded in 2025.
• Year-over-year, Total Liabilities tumbled 64.77% in 2024 and jumped 111.91% in 2025.
• Over 5 years, Total Liabilities stood at $16.2 million in 2022, then jumped by 59.96% to $25.9 million in 2023, then plunged by 64.77% to $9.1 million in 2024, then jumped by 54.58% to $14.1 million in 2025, then grew by 17.85% to $16.6 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $16.6 million in Q2 2026, $17.4 million in Q1 2026, and $14.1 million in Q4 2025.